Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
A phase 1/2 trial of Rondecabtagene autoleucel, Fludarabine, Cyclophosphamide in hodgkin lymphoma and non-hodgkin lymphoma, run by Lyell Immunopharma, Inc., now recruiting.
Overview
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma is a phase 1/2 interventional study registered as NCT05826535 by Lyell Immunopharma, Inc., with 270 participants planned, started 2023-05-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Shares Rondecabtagene autoleucel, Lyell Immunopharma, Hodgkin lymphoma.
- TrialA Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Shares Fludarabine, Cyclophosphamide, Non-Hodgkin lymphoma (all types).
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Fludarabine, Cyclophosphamide.